Difference between revisions of "BRST5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(45 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | ||
− | + | __TOC__ | |
<br /> | <br /> | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
Line 19: | Line 19: | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ====CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST)==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |Usual ductal hyperplasia |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 36: | Line 51: | ||
| | | | ||
|- | |- | ||
− | | | + | |Columnar cell lesions, including flat epithelial atypia||Disease|| |
| | | | ||
| | | | ||
Line 45: | Line 60: | ||
| | | | ||
|- | |- | ||
− | | | + | |Atypical ductal hyperplasia||Disease|| |
| | | | ||
| | | | ||
Line 54: | Line 69: | ||
| | | | ||
|- | |- | ||
− | | | + | |Sclerosing adenosis||Disease|| |
| | | | ||
| | | | ||
Line 63: | Line 78: | ||
| | | | ||
|- | |- | ||
− | | | + | |Apocrine adenosis and adenoma||Disease|| |
| | | | ||
| | | | ||
Line 72: | Line 87: | ||
| | | | ||
|- | |- | ||
− | | | + | |Microglandular adenosis||Disease|| |
| | | | ||
| | | | ||
Line 81: | Line 96: | ||
| | | | ||
|- | |- | ||
− | | | + | |Radial scar/complex sclerosing lesion||Disease|| |
| | | | ||
| | | | ||
Line 90: | Line 105: | ||
| | | | ||
|- | |- | ||
− | | | + | |Tubular adenoma||Disease|| |
| | | | ||
| | | | ||
Line 99: | Line 114: | ||
| | | | ||
|- | |- | ||
− | | | + | |Lactating adenoma||Disease|| |
| | | | ||
| | | | ||
Line 108: | Line 123: | ||
| | | | ||
|- | |- | ||
− | | | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |Ductal adenoma||Disease|| | ||
| | | | ||
| | | | ||
Line 117: | Line 143: | ||
| | | | ||
|- | |- | ||
− | | | + | |Pleomorphic adenoma||Disease|| |
| | | | ||
| | | | ||
Line 126: | Line 152: | ||
| | | | ||
|- | |- | ||
− | | | + | |Adenomyoepithelioma||Disease|| |
| | | | ||
| | | | ||
Line 135: | Line 161: | ||
| | | | ||
|- | |- | ||
− | | | + | |Malignant adenomyoepithelioma||Disease|| |
| | | | ||
| | | | ||
Line 144: | Line 170: | ||
| | | | ||
|- | |- | ||
− | | | + | |Intraductal papilloma||Disease|| |
| | | | ||
| | | | ||
Line 153: | Line 179: | ||
| | | | ||
|- | |- | ||
− | | | + | |Papillary ductal carcinoma in situ||Disease|| |
| | | | ||
| | | | ||
Line 162: | Line 188: | ||
| | | | ||
|- | |- | ||
− | | | + | |Encapsulated papillary carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 171: | Line 197: | ||
| | | | ||
|- | |- | ||
− | | | + | |Solid papillary carcinoma (in situ and invasive)||Disease|| |
| | | | ||
| | | | ||
Line 180: | Line 206: | ||
| | | | ||
|- | |- | ||
− | | | + | |Invasive papillary carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 189: | Line 215: | ||
| | | | ||
|- | |- | ||
− | | | + | |Atypical lobular hyperplasia||Disease|| |
| | | | ||
| | | | ||
Line 198: | Line 224: | ||
| | | | ||
|- | |- | ||
− | | | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |Lobular carcinoma in situ||Disease|| | ||
| | | | ||
| | | | ||
Line 207: | Line 244: | ||
| | | | ||
|- | |- | ||
− | | | + | |Ductal carcinoma in situ||Disease|| |
| | | | ||
| | | | ||
Line 216: | Line 253: | ||
| | | | ||
|- | |- | ||
− | | | + | |Invasive breast carcinoma of no special type||Disease|| |
| | | | ||
| | | | ||
Line 225: | Line 262: | ||
| | | | ||
|- | |- | ||
− | | | + | |Microinvasive carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 234: | Line 271: | ||
| | | | ||
|- | |- | ||
− | | | + | |Invasive lobular carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 243: | Line 280: | ||
| | | | ||
|- | |- | ||
− | | | + | |Tubular carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 252: | Line 289: | ||
| | | | ||
|- | |- | ||
− | | | + | |Cribriform carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 261: | Line 298: | ||
| | | | ||
|- | |- | ||
− | |Mucinous | + | |Mucinous carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 270: | Line 307: | ||
| | | | ||
|- | |- | ||
− | | | + | |Mucinous cystadenocarcinoma||Disease|| |
| | | | ||
| | | | ||
Line 279: | Line 316: | ||
| | | | ||
|- | |- | ||
− | | | + | |Invasive micropapillary carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 288: | Line 325: | ||
| | | | ||
|- | |- | ||
− | | | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |Carcinoma with apocrine differentiation||Disease|| | ||
| | | | ||
| | | | ||
Line 297: | Line 345: | ||
| | | | ||
|- | |- | ||
− | | | + | |Metaplastic carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 306: | Line 354: | ||
| | | | ||
|- | |- | ||
− | |Adenoid | + | |[[BRST5:Acinic cell carcinoma|Acinic cell carcinoma]]||Disease||Patricija Zot |
+ | |2/28/2024 | ||
+ | | | ||
+ | |PENDING | ||
+ | | | ||
+ | |Katherine Geiersbach | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[BRST5:Adenoid cystic carcinoma|Adenoid cystic carcinoma]]||Disease||Katherine Geiersbach / Jun Liao | ||
|10/12/02022 | |10/12/02022 | ||
|11/11/2023 | |11/11/2023 | ||
Line 315: | Line 372: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Secretory | + | |[[BRST5:Secretory carcinoma|Secretory carcinoma]]||Disease||Hui Chen / Morteza Seifi |
|10/12/2022 | |10/12/2022 | ||
|11/11/2023 | |11/11/2023 | ||
− | | | + | |COMPLETE |
| | | | ||
|Katherine Geiersbach | |Katherine Geiersbach | ||
Line 324: | Line 381: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Mucoepidermoid | + | |Mucoepidermoid carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 333: | Line 390: | ||
| | | | ||
|- | |- | ||
− | |Polymorphous | + | |Polymorphous adenocarcinoma||Disease|| |
| | | | ||
| | | | ||
Line 342: | Line 399: | ||
| | | | ||
|- | |- | ||
− | |Tall | + | |[[BRST5:Tall cell carcinoma with reversed polarity|Tall cell carcinoma with reversed polarity]]||Disease||H. Evin Gulbahce |
|8/11/2023 | |8/11/2023 | ||
|10/11/2023 | |10/11/2023 | ||
Line 351: | Line 408: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Neuroendocrine | + | |Neuroendocrine tumour||Disease|| |
| | | | ||
| | | | ||
Line 360: | Line 417: | ||
| | | | ||
|- | |- | ||
− | |Neuroendocrine | + | |Neuroendocrine carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 368: | Line 425: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | !'''Disease''' | ||
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | | | ||
+ | ====CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST)==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|Hamartoma||Disease|| | |Hamartoma||Disease|| | ||
Line 378: | Line 467: | ||
| | | | ||
|- | |- | ||
− | |Fibroadenoma||Disease||H. Evin Gulbahce / Patricija Zot | + | |[[BRST5:Fibroadenoma|Fibroadenoma]]||Disease||H. Evin Gulbahce / Patricija Zot |
|8/11/2023 | |8/11/2023 | ||
|11/11/2023 | |11/11/2023 | ||
Line 387: | Line 476: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Phyllodes | + | |[[BRST5:Phyllodes tumour|Phyllodes tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach |
|8/11/2023 | |8/11/2023 | ||
|11/11/2023 | |11/11/2023 | ||
− | | | + | |COMPLETE |
| | | | ||
| | | | ||
Line 396: | Line 485: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Syringomatous | + | | |
+ | ====CHAPTER 4 (TUMOURS OF THE NIPPLE)==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |Syringomatous tumour||Disease|| | ||
| | | | ||
| | | | ||
Line 405: | Line 515: | ||
| | | | ||
|- | |- | ||
− | |Nipple | + | |Nipple adenoma||Disease|| |
| | | | ||
| | | | ||
Line 414: | Line 524: | ||
| | | | ||
|- | |- | ||
− | |Paget disease of the | + | |Paget disease of the breast||Disease|| |
| | | | ||
| | | | ||
Line 422: | Line 532: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ====CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST)==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|Haemangioma||Disease|| | |Haemangioma||Disease|| | ||
Line 431: | Line 562: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | !'''Disease''' | ||
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
|- | |- | ||
|Angiomatosis||Disease|| | |Angiomatosis||Disease|| | ||
Line 441: | Line 583: | ||
| | | | ||
|- | |- | ||
− | |Atypical | + | |Atypical vascular lesions||Disease|| |
| | | | ||
| | | | ||
Line 450: | Line 592: | ||
| | | | ||
|- | |- | ||
− | |Postradiation | + | |Postradiation angiosarcoma of the breast||Disease|| |
| | | | ||
| | | | ||
Line 459: | Line 601: | ||
| | | | ||
|- | |- | ||
− | |Primary | + | |Primary angiosarcoma of the breast||Disease|| |
| | | | ||
| | | | ||
Line 468: | Line 610: | ||
| | | | ||
|- | |- | ||
− | |Nodular | + | |Nodular fasciitis||Disease|| |
| | | | ||
| | | | ||
Line 486: | Line 628: | ||
| | | | ||
|- | |- | ||
− | |Desmoid | + | |Desmoid fibromatosis||Disease|| |
| | | | ||
| | | | ||
Line 495: | Line 637: | ||
| | | | ||
|- | |- | ||
− | |Inflammatory | + | |[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||Yajuan Liu |
|8/11/2023 | |8/11/2023 | ||
|11/11/2023 | |11/11/2023 | ||
Line 522: | Line 664: | ||
| | | | ||
|- | |- | ||
− | |Granular | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |Granular cell tumour||Disease|| | ||
| | | | ||
| | | | ||
Line 576: | Line 729: | ||
| | | | ||
|- | |- | ||
− | |Pseudoangiomatous | + | |Pseudoangiomatous stromal hyperplasia||Disease|| |
| | | | ||
| | | | ||
Line 585: | Line 738: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
− | |||
| | | | ||
+ | ====CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)||Disease|| |
| | | | ||
| | | | ||
Line 612: | Line 768: | ||
| | | | ||
|- | |- | ||
− | | | + | |Follicular lymphoma||Disease|| |
| | | | ||
| | | | ||
Line 621: | Line 777: | ||
| | | | ||
|- | |- | ||
− | + | !'''Disease''' | |
− | + | !'''Page Type''' | |
− | + | !'''<span style="color:#0070C0">Author''' | |
− | + | !'''Date Assigned to Author''' | |
− | + | !'''Target Completion Date''' | |
− | + | !'''Author Content (Pending or Complete)''' | |
− | + | !'''Date Completed by Author''' | |
− | + | !'''Associate Editor''' | |
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
|- | |- | ||
− | | | + | |Diffuse large B-cell lymphoma||Disease|| |
| | | | ||
| | | | ||
Line 639: | Line 797: | ||
| | | | ||
|- | |- | ||
− | | | + | |Burkitt lymphoma||Disease|| |
| | | | ||
| | | | ||
Line 648: | Line 806: | ||
| | | | ||
|- | |- | ||
− | | | + | |Breast implant-associated anaplastic large cell lymphoma||Disease|| |
| | | | ||
| | | | ||
Line 657: | Line 815: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ====CHAPTER 7 (TUMOURS OF THE MALE BREAST)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |Gynaecomastia||Disease|| |
| | | | ||
| | | | ||
Line 684: | Line 845: | ||
| | | | ||
|- | |- | ||
− | | | + | |Carcinoma in situ||Disease|| |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 702: | Line 854: | ||
| | | | ||
|- | |- | ||
− | | | + | |Invasive carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 711: | Line 863: | ||
| | | | ||
|- | |- | ||
− | | | + | |Metastases to the breast||Disease|| |
| | | | ||
| | | | ||
Line 720: | Line 872: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
− | |||
| | | | ||
+ | ====CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[BRST5:BRCA1/2-associated hereditary breast and ovarian cancer syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | !'''Disease''' | ||
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |[[BRST5:Cowden syndrome|Cowden syndrome]]||Disease||[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[BRST5:Li-Fraumeni syndrome, TP53-associated|Li-Fraumeni syndrome, TP53-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[BRST5:CDH1-associated breast cancer|CDH1-associated breast cancer]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[BRST5:PALB2-associated cancers|PALB2-associated cancers]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[BRST5:Peutz-Jeghers syndrome|Peutz-Jeghers syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
|- | |- | ||
− | |Neurofibromatosis | + | |[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis type 1]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |Polygenic | + | |[[BRST5:Polygenic component of breast cancer susceptibility|Polygenic component of breast cancer susceptibility]] |
|Disease | |Disease | ||
+ | |Xiaolin Hu | ||
+ | |6/4/2024 | ||
| | | | ||
| | | | ||
Line 754: | Line 994: | ||
| | | | ||
| | | | ||
− | | | + | |Template added (6/4/24) |
− | |||
− | |||
|- | |- | ||
|}<br /> | |}<br /> |
Latest revision as of 13:52, 10 September 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
---|---|---|---|---|---|---|---|---|---|
CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST) |
|
|
|
|
|
|
|
|
|
Usual ductal hyperplasia | Disease | ||||||||
Columnar cell lesions, including flat epithelial atypia | Disease | ||||||||
Atypical ductal hyperplasia | Disease | ||||||||
Sclerosing adenosis | Disease | ||||||||
Apocrine adenosis and adenoma | Disease | ||||||||
Microglandular adenosis | Disease | ||||||||
Radial scar/complex sclerosing lesion | Disease | ||||||||
Tubular adenoma | Disease | ||||||||
Lactating adenoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Ductal adenoma | Disease | ||||||||
Pleomorphic adenoma | Disease | ||||||||
Adenomyoepithelioma | Disease | ||||||||
Malignant adenomyoepithelioma | Disease | ||||||||
Intraductal papilloma | Disease | ||||||||
Papillary ductal carcinoma in situ | Disease | ||||||||
Encapsulated papillary carcinoma | Disease | ||||||||
Solid papillary carcinoma (in situ and invasive) | Disease | ||||||||
Invasive papillary carcinoma | Disease | ||||||||
Atypical lobular hyperplasia | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Lobular carcinoma in situ | Disease | ||||||||
Ductal carcinoma in situ | Disease | ||||||||
Invasive breast carcinoma of no special type | Disease | ||||||||
Microinvasive carcinoma | Disease | ||||||||
Invasive lobular carcinoma | Disease | ||||||||
Tubular carcinoma | Disease | ||||||||
Cribriform carcinoma | Disease | ||||||||
Mucinous carcinoma | Disease | ||||||||
Mucinous cystadenocarcinoma | Disease | ||||||||
Invasive micropapillary carcinoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Carcinoma with apocrine differentiation | Disease | ||||||||
Metaplastic carcinoma | Disease | ||||||||
Acinic cell carcinoma | Disease | Patricija Zot | 2/28/2024 | PENDING | Katherine Geiersbach | ||||
Adenoid cystic carcinoma | Disease | Katherine Geiersbach / Jun Liao | 10/12/02022 | 11/11/2023 | COMPLETE | Hui Chen / Katherine Geiersbach | 12/6/2023 | 2021 template added | |
Secretory carcinoma | Disease | Hui Chen / Morteza Seifi | 10/12/2022 | 11/11/2023 | COMPLETE | Katherine Geiersbach | 2021 template added | ||
Mucoepidermoid carcinoma | Disease | ||||||||
Polymorphous adenocarcinoma | Disease | ||||||||
Tall cell carcinoma with reversed polarity | Disease | H. Evin Gulbahce | 8/11/2023 | 10/11/2023 | COMPLETE | Katherine Geiersbach | 2021 template added | ||
Neuroendocrine tumour | Disease | ||||||||
Neuroendocrine carcinoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST) |
|
|
|
|
|
|
|
|
|
Hamartoma | Disease | ||||||||
Fibroadenoma | Disease | H. Evin Gulbahce / Patricija Zot | 8/11/2023 | 11/11/2023 | PENDING | 2021 template added | |||
Phyllodes tumour | Disease | Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach | 8/11/2023 | 11/11/2023 | COMPLETE | 2021 template added | |||
CHAPTER 4 (TUMOURS OF THE NIPPLE) |
|
|
|
|
|
|
|
|
|
Syringomatous tumour | Disease | ||||||||
Nipple adenoma | Disease | ||||||||
Paget disease of the breast | Disease | ||||||||
CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST) |
|
|
|
|
|
|
|
|
|
Haemangioma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Angiomatosis | Disease | ||||||||
Atypical vascular lesions | Disease | ||||||||
Postradiation angiosarcoma of the breast | Disease | ||||||||
Primary angiosarcoma of the breast | Disease | ||||||||
Nodular fasciitis | Disease | ||||||||
Myofibroblastoma | Disease | ||||||||
Desmoid fibromatosis | Disease | ||||||||
Inflammatory myofibroblastic tumour | Disease | Yajuan Liu | 8/11/2023 | 11/11/2023 | COMPLETE | Katherine Geiersbach | 12/6/2023 | 2021 template added | |
Schwannoma | Disease | ||||||||
Neurofibroma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Granular cell tumour | Disease | ||||||||
Leiomyoma | Disease | ||||||||
Leiomyosarcoma | Disease | ||||||||
Lipoma | Disease | ||||||||
Angiolipoma | Disease | ||||||||
Liposarcoma | Disease | ||||||||
Pseudoangiomatous stromal hyperplasia | Disease | ||||||||
CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST) |
|
|
|
|
|
|
|
|
|
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) | Disease | ||||||||
Follicular lymphoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Diffuse large B-cell lymphoma | Disease | ||||||||
Burkitt lymphoma | Disease | ||||||||
Breast implant-associated anaplastic large cell lymphoma | Disease | ||||||||
CHAPTER 7 (TUMOURS OF THE MALE BREAST) |
|
|
|
|
|
|
|
|
|
Gynaecomastia | Disease | ||||||||
Carcinoma in situ | Disease | ||||||||
Invasive carcinoma | Disease | ||||||||
Metastases to the breast | Disease | ||||||||
CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST) |
|
|
|
|
|
|
|
|
|
BRCA1/2-associated hereditary breast and ovarian cancer syndrome | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Cowden syndrome | Disease | See DIG5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Ataxia-telangiectasia | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Li-Fraumeni syndrome, TP53-associated | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Li-Fraumeni syndrome, CHEK2-associated | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CDH1-associated breast cancer | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PALB2-associated cancers | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Peutz-Jeghers syndrome | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Neurofibromatosis type 1 | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Polygenic component of breast cancer susceptibility | Disease | Xiaolin Hu | 6/4/2024 | Template added (6/4/24) |